EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.69
-1.51 (-7.86%)
At close: 4:00PM EDT

17.83 +0.14 (0.79%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close19.20
Open19.16
Bid17.74 x 1100
Ask17.83 x 4000
Day's Range17.36 - 19.20
52 Week Range17.36 - 32.50
Volume8,307,964
Avg. Volume4,151,328
Market Cap5.272B
Beta2.04
PE Ratio (TTM)17.16
EPS (TTM)1.03
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.50
Trade prices are not sourced from all markets
  • 8 Undervalued Biotech Stocks to Watch
    InvestorPlace13 hours ago

    8 Undervalued Biotech Stocks to Watch

    From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.

  • Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation
    Motley Fool5 days ago

    Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation

    Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of EXEL earnings conference call or presentation 1-Aug-18 9:00pm GMT

    Q2 2018 Exelixis Inc Earnings Call

  • 13 of the Cheapest Healthcare Stocks
    Motley Fool7 days ago

    13 of the Cheapest Healthcare Stocks

    Each of these stocks has a PEG ratio below 1, but that doesn't make them all worth buying.

  • Here’s How Exelixis Is Financially Positioned Now
    Market Realist11 days ago

    Here’s How Exelixis Is Financially Positioned Now

    Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.

  • Cabozantinib Expected to Be Exelixis’s Long-Term Growth Driver
    Market Realist11 days ago

    Cabozantinib Expected to Be Exelixis’s Long-Term Growth Driver

    In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.

  • Analyst Recommendations for Exelixis in August
    Market Realist11 days ago

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.

  • See what the IHS Markit Score report has to say about Exelixis Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Exelixis Inc NASDAQ/NGS:EXEL

  • Exelixis Gets the Patients Eventually
    Motley Fool14 days ago

    Exelixis Gets the Patients Eventually

    Competing with immuno-oncology drugs might be hard, but being used after them is easy.

  • How United Therapeutics Fared in the Second Quarter of 2018
    Market Realist18 days ago

    How United Therapeutics Fared in the Second Quarter of 2018

    In the second quarter of 2018, United Therapeutics (UTHR) generated revenues of $444.5 million compared to $444.6 million in the second quarter of 2017. Its net revenues remained flat YoY (year-over-year), but there was an increase in the number of patients being treated with United Therapeutics’ therapies. In the second quarter of 2018, United Therapeutics reported net income of $172.9 million compared to a net loss of $56 million in the second quarter of 2017.

  • Here's Why Exelixis Stock Jumped Higher Today
    Motley Fool18 days ago

    Here's Why Exelixis Stock Jumped Higher Today

    The company hopped over investors' wall of worry.

  • Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2
    Zacks19 days ago

    Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2

    Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.

  • Exelixis (EXEL) Q2 Earnings and Revenues Surpass Estimates
    Zacks19 days ago

    Exelixis (EXEL) Q2 Earnings and Revenues Surpass Estimates

    Exelixis (EXEL) delivered earnings and revenue surprises of 86.67% and 21.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Exelixis: 2Q Earnings Snapshot

    The South San Francisco, California-based company said it had net income of 28 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire19 days ago

    Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    - Total Revenues of $186.1 million, Net Income of $87.5 million, Diluted EPS of $0.28 -

  • 3 Top Mid-Cap Stocks to Buy Right Now
    Motley Fool19 days ago

    3 Top Mid-Cap Stocks to Buy Right Now

    See why a music streaming leader, a cancer-drug developer, and a retail outlet REIT are compelling buys today.

  • See what the IHS Markit Score report has to say about Exelixis Inc.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Index (PMI) data, output in the Healthcare sector is rising.

  • Is Exelixis (EXEL) Poised for a Beat Again in Q2?
    Zacks24 days ago

    Is Exelixis (EXEL) Poised for a Beat Again in Q2?

    Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.

  • Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc.
    Motley Fool27 days ago

    Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc.

    Which stock wins in a one-on-one battle between these biotechs?

  • How Analysts View Exelixis ahead of Its Q2 2018 Results
    Market Realistlast month

    How Analysts View Exelixis ahead of Its Q2 2018 Results

    What Can Investors Expect from Exelixis’ Q2 2018 Results? In June, Exelixis (EXEL) announced that it would be added to the S&P MidCap 400 Index before the market opened on July 2. The S&P Dow Jones MidCap is one of the most highly reputed organizations, and its S&P MidCap 400 delivers investors a benchmark for midsize companies.

  • How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release
    Market Realistlast month

    How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release

    What Can Investors Expect from Exelixis’ Q2 2018 Results? Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1. Exelixis generated revenue of $134.2 million from product sales in the first quarter compared to $68.9 million in the first quarter of 2017.

  • Business Wirelast month

    Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018

    Exelixis, Inc. (EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

  • See what the IHS Markit Score report has to say about Exelixis Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.

  • Investopedialast month

    Top 5 Biotech Stocks for 2018

    Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.

  • Why Analysts are Mostly Positive On Acceleron Pharma
    Market Realistlast month

    Why Analysts are Mostly Positive On Acceleron Pharma

    After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.